Pharmacy

Your Article Summary

See Latest Articles

Sanofi Pasteur announces results of U.S. clinical trials in adults following one dose of influenza A (H1N1) vaccine
Sanofi-aventis, 10/02/09

Sanofi Pasteur, the vaccines division of the sanofi–aventis Group, announced an interim analysis of data from clinical trials of the U.S. licensed Influenza A (H1N1) 2009 Monovalent Vaccine in adults 18 years through 64 years of age and over the age of 65 years. These data indicate that a single 15 mcg dose of Sanofi Pasteur's Influenza A (H1N1) 2009 Monovalent Vaccine, administered to adults, including the oldest study participants, induces a robust antibody response 21 days post–vaccination that is considered protective.

Today in Dosing...keeping you current

Receive free subspecialty "5-minute updates" via email

Drug-Drug Interaction Between Itraconazole and the Protease Inhibitor Lopinavir/Ritonavir
Annals of Pharmacotherapy, 11/25/09

Impact of pharmaceutical dosage form on stability and dissolution of roxithromycin
Central European Journal of Medicine, 11/24/09

Postoperative analgesia with minidose intrathecal morphine for bipolar hip prosthesis in extremely elderly patients
Journal of Anesthesia, 11/24/09

 See all of Dosing

Today in Drug Trials...keeping you current

Receive free subspecialty "5-minute updates" via email

A 25-week, open-label trial investigating rivastigmine transdermal patches with concomitant memantine in mild-to-moderate Alzheimers disease: a post hoc analysis
Current Medical Research and Opinion, 11/25/09

Bayesian Modelling of Healthcare Resource Use in Multinational Randomized Clinical Trials
PharmacoEconomics, 11/24/09

Pandemic 2009 Influenza Update: Pandemrix data in children and adolescents from 3 to 17 years of age
GlaxoSmithKline, 11/24/09

 See all of Drug Trials